BioSpace News Archive

Keck Graduate Institute and Cardea Bio, publicly congratulates the Chief Scientific Officer of Cardea Bio, Dr. Kiana Aran, for being awarded the Distinguished Engineer, Medal of Excellence award from Rutgers University.

BrainScope Company Inc. announced its FDA-cleared, handheld, Class 2 medical device that uses artificial intelligence and machine learning technology to identify objective biomarkers of structural (intracranial hemorrhage) and functional (concussion) brain injury in patients with suspected mild traumatic brain injury (mTBI) has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that positive results from a collaborative project with University of Alberta researchers have been accepted for publication in The Journal of Supercritical Fluids.

CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022.

Bluestem Biosciences, a renewable chemicals company maximizing agriculture and energy infrastructure through synthetic biology, announced a pre-seed financing round of $5 million.

SK Biopharmaceuticals, Co., Ltd. announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration (“FDA”) on August 8th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.

Avenda Health, an AI healthcare company creating the future of prostate cancer care, today announced its FocalPoint ablation system powered by iQuest, a patient management AI software, has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA).

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), today announced that it has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin its 15 patient study evaluating REM-001 Photodynamic Therapy (PDT) for the treatment of Cutaneous Metastatic Breast Cancer (CMBC).